LAUSR

143 Regarding safety outcomes, SGLT2 inhibitors do not seem to increase the risk of hypoglyce‐ mia, while a previous meta ‐analysis demonstrated that, when added to metformin, SGLT ‐2 inhibitors are associated with the lowest odds for hypogly‐ cemia, compared with the remaining second ‐line oral antidiabetic agents.5 Of course, extra caution is needed as far as the risk of diabetic ketoacido‐ sis and lower extremity amputation is concerned.2 An appropriate adjustment of the remaining an‐ tidiabetic regimen may be needed. Overall, the insulin ‐independent mechanism of action and the multilevel pleiotropic effects of SGLT2 inhibitors make them an attractive treat‐ ment option in the elderly population. Oral once‐ ‐daily administration and availability of fixed com‐ binations with metformin might also be consid‐ ered as an advantage. However, this hypothesis needs to be tested in large prospective clinical tri‐ als with SGLT2 inhibitors, enrolling exclusively the geriatric population.